|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Previously, we observed p53 mutations in the noncancerous tissue that differed from those in lung tumors using the highly sensitive p53 mutation load assay.
|
16912213 |
2006 |
|
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
BEFREE |
Lung tumors in old mice displayed higher proliferation rates, as well as attenuated DNA damage and p53 tumor suppressor responses.
|
29047229 |
2018 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
LHGDN |
Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers.
|
17280505 |
2007 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Three different patterns in the distribution of p53 mutations in double lung tumours were observed: [A] mutation in only one of the tumours (four cases), [B] different mutations in the tumours (two cases), and [C] same mutation in both tumours (one case).
|
10188905 |
1999 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors.
|
12552590 |
2003 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
LHGDN |
Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
|
16287156 |
2006 |
|
Lung Neoplasms
|
0.800 |
AlteredExpression
|
group |
LHGDN |
Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis.
|
14676844 |
2004 |
|
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
CTD_human |
Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent.
|
20727180 |
2010 |
|
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
CTD_human |
[Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82].
|
11798837 |
2000 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
LHGDN |
Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis.
|
18259947 |
2008 |
|
Lung Neoplasms
|
0.800 |
Therapeutic
|
group |
CTD_human |
Genomic landscape of cutaneous T cell lymphoma.
|
26192916 |
2015 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Lung tumors from 204 smokers with non-small cell lung cancer (NSCLC) were analyzed for mutations in exons 5-8 of the p53 gene and genotypes of XPD and XRCC1. p53 mutations were found in 20% (40/204) of the patients.
|
12844488 |
2003 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
LHGDN |
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
|
17575133 |
2007 |
|
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
LHGDN |
The extract of Hibiscus syriacus inducing apoptosis by activating p53 and AIF in human lung cancer cells.
|
18306460 |
2008 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Alterations of p53 are one of the most common molecular changes found in all types of lung tumors, suggesting a crucial role for p53 in bronchial carcinogenesis.
|
8389245 |
1993 |
|
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
BEFREE |
The mean in vitro bleomycin-induced breaks per cell (a marker of cancer susceptibility) was significantly higher (0.92) for patients who overexpressed p53 in lung tumour tissue than that for patients with no detectable p53 expression in lung tumour tissue (0.65).
|
10408853 |
1999 |
|
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
CTD_human |
Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
|
17325666 |
2007 |
|
Lung Neoplasms
|
0.800 |
Therapeutic
|
group |
CTD_human |
[Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82].
|
11798837 |
2000 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Sixty-four tumors in 31 patients with synchronous and metachronous lung tumors were investigated by p53 mutation analysis.
|
11815976 |
2002 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
In two cases, the lung tumors exhibited a p53 mutation not present in the previously removed primary tumor and were therefore classified as new primary lung cancers.
|
8614143 |
1996 |
|
Lung Neoplasms
|
0.800 |
AlteredExpression
|
group |
BEFREE |
There was, in general, an excellent concordance between the lung tumor cell lines and their corresponding tumor tissues for morphology (100%), the presence of aneuploidy (100%), immunohistochemical expression of HER2/neu (100%) and p53 proteins (100%), loss of heterozygosity at 13 chromosomal regions analyzed (97%) using 37 microsatellite markers, microsatellite alterations (MAs, 75%), TP53 (67%), and K-ras (100%) gene mutations.
|
10353731 |
1999 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Protein overexpression in primary lung tumors was limited to squamous cell carcinoma and tumors known to harbor a high frequency of p53 mutations.
|
10805802 |
2000 |
|
Lung Neoplasms
|
0.800 |
Biomarker
|
group |
BEFREE |
The authors sequenced the EGFR-TK domain and the K-ras and p53 genes from lung tumor tissues from 44 never smokers and 46 smokers.
|
17409930 |
2006 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
In conclusion, common genetic variation in TP53 could modulate lung cancer pathways, as suggested by the association with lung cancer in African Americans and somatic TP53 mutation frequency in lung tumors.
|
17301252 |
2007 |
|
Lung Neoplasms
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Analysis of genetic changes in lung tumors showed that the incidence of mutations in the TP53 and KRAS genes and the incidence of LOH in the FHIT gene were significantly greater in smokers versus non-smokers (P < 0.01).
|
17693665 |
2007 |